Terms: = Breast cancer AND LMNA, EMD2, 4000, ENSG00000160789, LGMD1B, LDP1, PRO1, LMNC, FPLD, CDDC, HGPS, P02545, LFP, IDC, CMD1A, CDCD1, LMN1, CMT2B1, FPL AND Treatment
492 results:
1. Differentiation of invasive ductal and lobular carcinoma of the breast using MRI radiomic features: a pilot study.
Maiti S; Nayak S; Hebbar KD; Pendem S
F1000Res; 2024; 13():91. PubMed ID: 38571894
[TBL] [Abstract] [Full Text] [Related]
2. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.
Wang J; Li B; Luo M; Huang J; Zhang K; Zheng S; Zhang S; Zhou J
Signal Transduct Target Ther; 2024 Apr; 9(1):83. PubMed ID: 38570490
[TBL] [Abstract] [Full Text] [Related]
3. Intraoperative Evaluation of breast Tissues During breast cancer Operations Using the MasSpec Pen.
Garza KY; King ME; Nagi C; DeHoog RJ; Zhang J; Sans M; Krieger A; Feider CL; Bensussan AV; Keating MF; Lin JQ; Sun MW; Tibshirani R; Pirko C; Brahmbhatt KA; Al-Fartosi AR; Thompson AM; Bonefas E; Suliburk J; Carter SA; Eberlin LS
JAMA Netw Open; 2024 Mar; 7(3):e242684. PubMed ID: 38517441
[TBL] [Abstract] [Full Text] [Related]
4. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
5. [A Case of Triple Negative breast cancer with Successful Control of Recurrent Disease Activity for More than Ten Years].
Yabe N; Watanuki R; Harada Y; Kondo A; Yanagisawa T; Maeda H; Kishi M; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Jinno H; Ikeda T; Watanabe M
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1759-1761. PubMed ID: 38303198
[TBL] [Abstract] [Full Text] [Related]
6. Tumor microenvironment and immune system preservation in early-stage breast cancer: routes for early recurrence after mastectomy and treatment for lobular and ductal forms of disease.
Saad HA; Baz A; Riad M; Eraky ME; El-Taher A; Farid MI; Sharaf K; Said HEM; Ibrahim LA
BMC Immunol; 2024 Jan; 25(1):9. PubMed ID: 38273260
[TBL] [Abstract] [Full Text] [Related]
7. Using hybrid pre-trained models for breast cancer detection.
Zarif S; Abdulkader H; Elaraby I; Alharbi A; Elkilani WS; Pławiak P
PLoS One; 2024; 19(1):e0296912. PubMed ID: 38252633
[TBL] [Abstract] [Full Text] [Related]
8. Chemotherapy is of prognostic significance to metaplastic breast cancer.
Zhang M; Yuan J; Wang M; Zhang M; Chen H
Sci Rep; 2024 Jan; 14(1):1210. PubMed ID: 38216630
[TBL] [Abstract] [Full Text] [Related]
9. TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2
Shao X; Yang D; Shan L; Yan X; Xu D; Li L; Sun Y; Yu Q; Zhou H; Ding Y; Tang J
Arch Toxicol; 2024 Mar; 98(3):865-881. PubMed ID: 38212449
[TBL] [Abstract] [Full Text] [Related]
10. Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types.
Andrianto A; Sudiana IK; Suprabawati DGA; Notobroto HB
F1000Res; 2023; 12():841. PubMed ID: 38046195
[No Abstract] [Full Text] [Related]
11. Clinicopathological characteristics and prognosis of metaplastic breast cancer versus triple-negative invasive ductal carcinoma: a retrospective analysis.
Yang X; Tang T; Zhou T
World J Surg Oncol; 2023 Nov; 21(1):364. PubMed ID: 37996840
[TBL] [Abstract] [Full Text] [Related]
12. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).
Antolín Novoa S; Escrivá-de-Romaní S; Tolosa Ortega P; Oliva Fernández L; López López R; López González A; de la Morena Barrio P; Echavarria Díaz-Guardamino I; Alés Martinez JE; Garate Z; González-Cortijo L
Cancer Treat Res Commun; 2023; 37():100772. PubMed ID: 37995519
[TBL] [Abstract] [Full Text] [Related]
13. Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma.
Yoon TI; Jeong J; Lee S; Ryu JM; Lee YJ; Lee JY; Hwang KT; Kim H; Kim S; Lee SB; Ko BS; Lee JW; Son BH; Metzger O; Kim HJ
JAMA Netw Open; 2023 Nov; 6(11):e2342270. PubMed ID: 37938845
[TBL] [Abstract] [Full Text] [Related]
14. The uncharted role of HER2 mutant alleles in breast cancer.
Kalra R; Lim B; Ellis MJ; Kavuri SM
Oncotarget; 2023 Oct; 14():904-907. PubMed ID: 37921670
[TBL] [Abstract] [Full Text] [Related]
15. Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.
Avatefi M; HadavandSiri F; Nazari SSH; Akbari ME
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1927. PubMed ID: 37919558
[TBL] [Abstract] [Full Text] [Related]
16. Investigation of the miR-637 and miR-523-5p as candidate biomarkers in breast cancer.
Coskunpinar E; Tiryakioglu DZ; Abaci N; Tukenmez M; Pence S
Bratisl Lek Listy; 2023; 124(11):814-820. PubMed ID: 37874803
[TBL] [Abstract] [Full Text] [Related]
17. Assessment of breast cytoarchitecture and its associated axillary lymph node status under normal and pathological conditions in Egyptian women.
Mansour O; Kazem A; El Wakil A
Tissue Cell; 2023 Dec; 85():102244. PubMed ID: 37856936
[TBL] [Abstract] [Full Text] [Related]
18. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National cancer Database (NCDB).
Rothschild HT; Clelland EN; Abel MK; Chien AJ; Shui AM; Esserman L; Khan SA; Mukhtar RA
Breast Cancer Res Treat; 2024 Jan; 203(2):245-256. PubMed ID: 37833450
[TBL] [Abstract] [Full Text] [Related]
19. Metaplastic breast carcinoma: Analysis of clinical and pathologic features, a five-year study.
Chaudhary D; Balhara K; Mandal S; Mallya V; Tomar R; Khurana N; Bains L
J Cancer Res Ther; 2023; 19(5):1226-1230. PubMed ID: 37787287
[TBL] [Abstract] [Full Text] [Related]
20. Turning the Page on breast cancer in Ohio: Lessons learned from implementing a multilevel intervention to reduce breast cancer mortality among Black women.
Padamsee TJ; Stover DG; Tarver WL; Washington CM; Baltic RD; DeGraffinreid CR; Whiting CRB; Rumano R; Lee CN; Nolan T; Oppong B; Obeng-Gyasi S; Toland AE; Bernardo B; Hampel H; Paskett ED
Cancer; 2023 Sep; 129(S19):3114-3127. PubMed ID: 37691524
[TBL] [Abstract] [Full Text] [Related]
[Next]
